Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine

被引:11
作者
Tang, Hsin-Chieh [1 ]
Chen, Calvin Yu-Chian [1 ,2 ,3 ,4 ]
机构
[1] Asia Univ, Dept Biomed Informat, Taichung 41354, Taiwan
[2] China Med Univ, Dept Med, Taichung 40402, Taiwan
[3] China Med Univ, Res Ctr Chinese Med & Acupuncture, Taichung 40402, Taiwan
[4] China Med Univ Hosp, Dept Med Res, Human Genet Ctr, Taichung 40447, Taiwan
关键词
CELL-CYCLE; PROTEIN; CANCER; RESISTANCE; EXPRESSION; POTENT; CDK2; GENE; P21; SIMULATION;
D O I
10.1155/2014/798742
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
One has found an important cell cycle controller. This guard can decide the cell cycle toward proliferation or quiescence. Cyclin-dependent kinase 2 (CDK2) is a unique target among the CDK family in melanoma therapy. We attempted to find out TCM compounds from TCM Database@Taiwan that have the ability to inhibit the activity of CDK2 by systems biology. We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates by docking and screening results for further survey. We utilized support vectormachine (SVM), multiple linear regression (MLR) models and Bayesian network for validation of predicted activity. By overall analysis of docking results, predicted activity, and molecular dynamics (MD) simulation, we could conclude that Tetrahydropalmatine, Reserpiline, and (+)-Corydaline had better binding affinity than the control. All of them had the ability to inhibit the activity of CDK2 and might have the opportunity to be applied in melanoma therapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Virtual Screening for Potential Allosteric Inhibitors of Cyclin-Dependent Kinase 2 from Traditional Chinese Medicine
    Lu, Fang
    Luo, Ganggang
    Qiao, Liansheng
    Jiang, Ludi
    Li, Gongyu
    Zhang, Yanling
    MOLECULES, 2016, 21 (09)
  • [2] Targeting the cyclin-dependent kinase 5 in metastatic melanoma
    Sharma, Samanta
    Zhang, Tian
    Michowski, Wojciech
    Rebecca, Vito W.
    Xiao, Min
    Ferretti, Roberta
    Suski, Jan M.
    Bronson, Roderick T.
    Paulo, Joao A.
    Frederick, Dennie
    Fassl, Anne
    Boland, Genevieve M.
    Geng, Yan
    Lees, Jacqueline A.
    Medema, Rene H.
    Herlyn, Meenhard
    Gygi, Steven P.
    Sicinski, Piotr
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (14) : 8001 - 8012
  • [3] Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma
    Julve, Maximilian
    Clark, James J.
    Lythgoe, Mark P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (03) : 351 - 361
  • [4] Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
    Dolman, M. Emmy M.
    Poon, Evon
    Ebus, Marli E.
    den Hartog, Ilona J. M.
    van Noesel, Carel J. M.
    Jamin, Yann
    Hallsworth, Albert
    Robinson, Simon P.
    Petrie, Kevin
    Sparidans, Rolf W.
    Kok, Robbert J.
    Versteeg, Rogier
    Caron, Huib N.
    Chesler, Louis
    Molenaar, Jan J.
    CLINICAL CANCER RESEARCH, 2015, 21 (22) : 5100 - 5109
  • [5] The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
    Tanaka, Tomohito
    Terai, Yoshito
    Ashihara, Keisuke
    Fujiwara, Satoe
    Tanaka, Yoshimichi
    Sasaki, Hiroshi
    Tsunetoh, Satoshi
    Ohmichi, Masahide
    PLOS ONE, 2017, 12 (05):
  • [6] Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
    Kaszubski, Jonatan
    Gagat, Maciej
    Grzanka, Alina
    Wawrzyniak, Agata
    Niklinska, Wieslawa
    Lapot, Magdalena
    Zuryn, Agnieszka
    MOLECULES, 2024, 29 (22):
  • [7] The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
    Desai, Brijal M.
    Villanueva, Jessie
    Nguyen, Thierry-Thien K.
    Lioni, Mercedes
    Xiao, Min
    Kong, Jun
    Krepler, Clemens
    Vultur, Adina
    Flaherty, Keith T.
    Nathanson, Katherine L.
    Smalley, Keiran S. M.
    Herlyn, Meenhard
    PLOS ONE, 2013, 8 (03):
  • [8] Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor
    Gebbia, Vittorio
    Valerio, Maria Rosaria
    Firenze, Alberto
    Vigneri, Paolo
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (08) : 945 - 953
  • [9] Development of a cyclin-dependent kinase inhibitor devoid of ABC transporterdependent drug resistance
    Kaliszczak, M.
    Patel, H.
    Kroll, S. H. B.
    Carroll, L.
    Smith, G.
    Delaney, S.
    Heathcote, D. A.
    Bondke, A.
    Fuchter, M. J.
    Coombes, R. C.
    Barrett, A. G. M.
    Ali, S.
    Aboagye, E. O.
    BRITISH JOURNAL OF CANCER, 2013, 109 (09) : 2356 - 2367
  • [10] Expression of the cyclin-dependent kinase inhibitor Dacapo is regulated by Cyclin E
    de Nooij, JC
    Graber, KH
    Hariharan, IK
    MECHANISMS OF DEVELOPMENT, 2000, 97 (1-2) : 73 - 83